Telix Pharmaceuticals has ridden a long upward stretch over the past five years, and the latest deal and product news add fresh weight to an old question. Are investors now paying a share price that is fully backed by the cash flows Telix can generate over time, or is the market getting ahead of itself?
- Over the past 5 years, Telix Pharmaceuticals has delivered a share price gain of 188.5%, which puts its current valuation firmly under the spotlight for anyone focused on the durability of its cash flows.
- The planned acquisition of ITM Isotope Technologies Munich for up to US$2.35b may support Telix's long term revenue and cash flow potential, while also increasing funding needs and execution risk as the combined business is built out.
- Prefer to judge Telix Pharmaceuticals on earnings? See why Telix Pharmaceuticals's 121.2x P/E tells a different valuation story.
For investors, the debate is whether Telix Pharmaceuticals' current share price is appropriately grounded in the cash flows implied by its Discounted Cash Flow (DCF) intrinsic value estimate.
If you are weighing Telix Pharmaceuticals against other opportunities built on cash flow durability, it can help to compare it with companies filtered through our 5 high quality undervalued stocks.
Is Telix Pharmaceuticals Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model here projects what Telix Pharmaceuticals might generate for shareholders based on its future free cash flows. The latest twelve month free cash flow shows a loss of $50.56 million, so this valuation leans heavily on expectations that the business shifts from cash burn to positive cash generation over the next decade, with projected free cash flow moving into the hundreds of millions of dollars.
Because those projections assume a rising cash flow profile, the model currently places Telix Pharmaceuticals' estimated intrinsic worth substantially above the A$16.79 share price. The planned US$2.35b acquisition of ITM Isotope Technologies Munich helps explain why the market is still hesitating, since extra funding needs and integration work sit on the same path as the higher cash flow potential that the DCF is capturing. Find out what Telix Pharmaceuticals could be worth using our Discounted Cash Flow (DCF) estimate.
The Telix Pharmaceuticals Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Telix Pharmaceuticals valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than its current price on any given view.
Each narrative ties its number to a clear stance on how Telix Pharmaceuticals' expansion, profitability profile and key risks could evolve over time, giving you a reference point you can return to as new information comes through on the Community page.
One of the top community narratives on Telix Pharmaceuticals: 7% undervalued
"Telix develops and commercialises radiopharmaceutical products, basically, precision imaging agents and therapeutics that help doctors find and (eventually) destroy tumours..."
Discover why this Narrative puts Telix Pharmaceuticals at 7% undervalued.
For Telix Pharmaceuticals, who is steering the ship?
Numbers only tell part of the story, because the people setting Telix Pharmaceuticals' priorities and how they are rewarded can pull returns toward or away from those projections. See who runs Telix Pharmaceuticals and how they are paid.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com